壳聚糖（CS）是一种具有生物活性的生物聚合物，由于其生物可降解性、生物相容性和无毒性，可用于不同的医疗应用。纳米技术是医疗应用中一个令人兴奋且快速发展的领域。纳米颗粒在治疗癌症和炎症方面显示出巨大的潜力。在目前的工作中，N-氨基邻苯二甲酰亚胺（NAP）对壳聚糖及其（Ag、Au或ZnO）纳米复合材料的改性是通过与环氧氯丙烷（ECH）作为交联剂在存在或不存在戊二醛（GA）的情况下在不同反应下发生的反应来实现的。条件下利用微波辐射得到改性壳聚糖衍生物CS-2、CS-6及其纳米复合材料。使用不同的工具对改性壳聚糖衍生物进行表征。与壳聚糖相比，CS-2 和 CS-6 衍生物表现出热稳定性和结晶度的增强。此外，与壳聚糖相比，CS-2、CS-6 及其纳米复合材料对 HeLa 癌细胞的抗肿瘤活性以及对胰蛋白酶和 α-胰凝乳蛋白酶的酶抑制活性有所提高。然而，CS-2对HeLa细胞显示出最高的细胞生长抑制%（89.02±1.46%）和对α-胰凝乳蛋白酶的酶抑制（17.13±1.59%）。此外，CS-Au-2 对胰蛋白酶表现出最高的酶抑制作用（28.14±1.76%）。这些结果表明，新型壳聚糖衍生物 CS-2、CS-6 及其纳米复合材料可以成为针对 HeLa 细胞、胰蛋白酶和 α-胰凝乳蛋白酶的医学应用平台。版权所有 © 2023 Elsevier B.V. 保留所有权利。

Chitosan (CS) is a biologically active biopolymer used in different medical applications due to its biodegradability, biocompatibility, and nontoxicity. Nanotechnology is an exciting and quick developing field in medical applications. Nanoparticles have shown great potential in the treatment of cancer and inflammation. In the present work modification of chitosan and its (Ag, Au, or ZnO) nanocomposites by N-aminophthalimide (NAP) occurred through the reaction with epichlorohydrin (ECH) as a crosslinker in the presence or absence of glutaraldehyde (GA) under different reaction conditions using microwave irradiation to give modified chitosan derivatives CS-2, CS-6, and their nanocomposites. Modified chitosan derivatives were characterized using different tools. CS-2 and CS-6 derivatives displayed enhancement of thermal stability and crystallinity compared to chitosan. Additionally, CS-2, CS-6, and their nanocomposites exhibited improvements in antitumor activity against HeLa cancer cells and enzymatic inhibitory against trypsin and α-chymotrypsin enzymes compared to chitosan. However, CS-2 revealed the highest cell growth inhibition% toward HeLa cells (89.02 ± 1.46 %) and the enzymatic inhibitory toward α-chymotrypsin enzyme (17.13 ± 1.59 %). Furthermore, CS-Au-2 showed the highest enzymatic inhibitory against trypsin enzyme (28.14 ± 1.76 %). These results suggested that the new chitosan derivatives CS-2, CS-6, and their nanocomposites could be a platform for medical applications against HeLa cells, trypsin, and α-chymotrypsin enzymes.Copyright © 2023 Elsevier B.V. All rights reserved.